The FDA granted accelerated approval to the first targeted therapeutic and a companion diagnostic for certain adult patients with non-small cell lung cancer that tests positive for specific mutations in a protein that helps...
The FDA has approved an immunotherapeutic for certain patients with these cancers who had their cancer completely resected and received chemoradiotherapy before surgery. The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic nivolumab...
Study suggests ovarian cancer screening does not reduce mortality, and more news of the week from Cancer Today.
Since 2014, the American Association for Cancer Research (AACR) has invited early-career investigators to apply to the NextGen Stars program, which provides awardees the opportunity to present their research on a global stage at the AACR Annual Meeting. The enhanced visibility granted by the NextGen Stars program has...
A Food and Drug Administration panel recommends withdrawing approvals for two treatment indications for immunotherapy drugs, and more news of the week from Cancer Today.
Cancers of the blood can initiate in a variety of cells, including in white blood cells (giving rise to lymphoma and leukemia) or in plasma cells (giving rise to myeloma). In 2020 alone, there were an estimated 1.3 million new blood cancer cases worldwide, which accounted for more than 5 percent of all cancer diagnoses that...
The FDA has granted accelerated approval to an immunotherapeutic to be used in combination with a targeted therapeutic and chemotherapy to treat certain patients with gastric or gastroesophageal junction adenocarcinomas. The U.S. Food and...
Many patients facing a cancer diagnosis ask their doctors a simple question: “What should I eat?” That elemental question has perplexed scientists for centuries. In a stirring discussion during the Opening Plenary session of...
President Biden resurfaces a proposal for a new health care agency, and more news of the week from Cancer Today.
The term “cancer” encompasses a broad range of diseases that can afflict almost any organ of the body. Not only do molecular features and clinical outcomes vary widely between different cancer types, but they can even differ between individuals who have...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now